About this trial
In the context of environmental pollution of the French West Indies by chlordecone and questions about health consequences, monitoring at the peripubertal age of children born alive in the TIMOUN cohort is justified in several respects: - existence of an already established mother-child cohort whose live-born children will reach peripubertal ages during the period 2020-2022; - opportunity to verify hypotheses put forward on the basis of toxicological data acquired in laboratory animals and the hormonal characteristics of chlordecone (endocrine disruptor); - strong societal demand for such research to be carried out because of concerns about the sensitivity of children and adolescents to the effects of environmental xenobiotics, in particular on sexual development and the age of puberty; - recommendation of the Scientific Council Chlordecone Inserm - InVS; specific action of the National Plan Chlordecone IV.
Eligibility criteria
Qualifiers
Be born to a mother whose pregnancy was included in the Timoun cohort (2004 - 2007) and whose parents agreed to be contacted later.
Residing in Guadeloupe at the peripubertal age
Affiliation to a social security scheme
Agreement to participate in the study and informed consent signed by the minor
Disqualifiers
Refusal to participate in the research
Trial design
Treatments tested in this trial
- Clinical examination
Treatment groups
Sponsors and collaborators
Centre Hospitalier Universitaire de la Guadeloupe
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborator